Literature DB >> 15145175

Spinal cord tolerance to high-dose fractionated 3D conformal proton-photon irradiation as evaluated by equivalent uniform dose and dose volume histogram analysis.

Laura Marucci1, Andrzej Niemierko, Norbert J Liebsch, Fethiya Aboubaker, Mitchell C C Liu, J E Munzenrider.   

Abstract

PURPOSE: To evaluate cervical spinal cord tolerance using equivalent uniform dose (EUD) and dose volume histogram (DVH) analysis after proton-photon radiotherapy. METHODS AND MATERIAL: The 3D dose distributions were analyzed in 85 patients with cervical vertebral tumors. Mean follow-up was 41.3 months. The mean prescribed dose was 76.3 Cobalt Gray Equivalent (CGE = proton dose x RBE 1.1). Dose constraints to the center and the surface of the cervical cord were 55-58 CGE and 67-70 CGE, respectively. Dose parameters, DVH and EUD, were calculated for each patient. The spinal cord toxicity was graded using the European Organization for Research and Treatment of Cancer (EORTC) and Radiation Therapy Oncology Group (RTOG) late effects scoring system.
RESULTS: Thirteen patients experienced Grade 1-2 toxicity. Four patients had Grade 3 toxicity. For the dose range used in this study, none of the dosimetric parameters was found to be associated with the observed distribution of cord toxicities. The only factor significantly associated with cord toxicity was the number of surgeries before irradiation.
CONCLUSION: The data and our analysis suggest that the integrity of the normal musculoskeletal supportive tissues and vascular supply may be important confounding factors of toxicity at these dose levels. The results also indicate that the cervical spinal cord dose constraints used in treating these patients are appropriate for conformal proton-photon radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15145175     DOI: 10.1016/j.ijrobp.2003.10.058

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Delayed onset of paresis in rats with experimental intramedullary spinal cord gliosarcoma following intratumoral administration of the paclitaxel delivery system OncoGel.

Authors:  Betty M Tyler; Alia Hdeib; Justin Caplan; Federico G Legnani; Kirk D Fowers; Henry Brem; George Jallo; Gustavo Pradilla
Journal:  J Neurosurg Spine       Date:  2012-01

2.  Predicting Patient-specific Dosimetric Benefits of Proton Therapy for Skull-base Tumors Using a Geometric Knowledge-based Method.

Authors:  David C Hall; Alexei V Trofimov; Brian A Winey; Norbert J Liebsch; Harald Paganetti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-02-14       Impact factor: 7.038

3.  Spinal cord constraints in the era of high-precision radiotherapy : Retrospective analysis of 62 spinal/paraspinal lesions with possible infringements of spinal cord constraints within a minimal volume.

Authors:  Sebastian Zschaeck; Peter Wust; Reinhold Graf; Waldemar Wlodarczyk; Reinhard Schild; Alexander Henry Thieme; Mirko Weihrauch; Volker Budach; Pirus Ghadjar
Journal:  Strahlenther Onkol       Date:  2017-05-02       Impact factor: 3.621

4.  Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus.

Authors:  Feng-Ming Spring Kong; Timothy Ritter; Douglas J Quint; Suresh Senan; Laurie E Gaspar; Ritsuko U Komaki; Coen W Hurkmans; Robert Timmerman; Andrea Bezjak; Jeffrey D Bradley; Benjamin Movsas; Lon Marsh; Paul Okunieff; Hak Choy; Walter J Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-08       Impact factor: 7.038

5.  Tumours of the atlas and axis: a 37-year experience with diagnosis and management.

Authors:  A F Mavrogenis; G Guerra; M Romantini; C Romagnoli; R Casadei; P Ruggieri
Journal:  Radiol Med       Date:  2011-11-17       Impact factor: 3.469

6.  Synchronous metastatic skull base chordoma to the breast: case report and literature review.

Authors:  S I Shakir; M Pelmus; A Florea; J F Boileau; M C Guiot; S Di Maio; T M Muanza
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

7.  Parotid gland dose in intensity-modulated radiotherapy for head and neck cancer: is what you plan what you get?

Authors:  Jennifer C O'Daniel; Adam S Garden; David L Schwartz; He Wang; Kian K Ang; Anesa Ahamad; David I Rosenthal; William H Morrison; Joshua A Asper; Lifei Zhang; Shih-Ming Tung; Radhe Mohan; Lei Dong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.